Anticholinergic burden and its predictors among patients with schizophrenia in Northwest Ethiopia: An institutional-based cross sectional study.

IF 5 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Psychopharmacology Pub Date : 2026-08-21 eCollection Date: 2026-01-01 DOI:10.1177/20451253261481515

Fasil Bayafers Tamene, Getachew Yitayew Tarekegn, Tilaye Arega Moges, Samuel Berihun Dagnew, Tigabu Eskeziya Zerihun, Abel Temeche Kassaw, Desalegn Addis Mussie, Woretaw Sisay Zewdu, Samuel Agegnew Wondm

{"title":"Anticholinergic burden and its predictors among patients with schizophrenia in Northwest Ethiopia: An institutional-based cross sectional study.","authors":"Fasil Bayafers Tamene, Getachew Yitayew Tarekegn, Tilaye Arega Moges, Samuel Berihun Dagnew, Tigabu Eskeziya Zerihun, Abel Temeche Kassaw, Desalegn Addis Mussie, Woretaw Sisay Zewdu, Samuel Agegnew Wondm","doi":"10.1177/20451253261481515","DOIUrl":null,"url":null,"abstract":"Background: Many drugs prescribed for individuals with schizophrenia have anticholinergic effects. When these medications are used together, they can create a substantial overall Anticholinergic Burden (ACB).Objective: The aim of this study was to assess the prevalence of ACB and its predictors among patients with schizophrenia at selected comprehensive specialized hospitals in Northwest Ethiopia.Design: A multicenter cross sectional study was conducted.Methods: The study included 406 patients with schizophrenia at selected specialized hospitals in Northwest Ethiopia between June and August 2022. Study participants were recruited using systematic random sampling. The Anticholinergic Cognitive Burden Score (ACBS) was used to assess ACB. Data were entered using EpiData version 4.6.0 and analyzed with SPSS version 26. Multivariable logistic regression analysis was performed to determine the predictors of high ACB, with variables having a p-value < 0.05 at a 95% confidence interval considered statistically significant.Results: The prevalence of high ACB was 34.2%. Older patients [Adjusted Odds Ratio (AOR) = 3.26, 95% CI: 1.17, 9.08 P: 0.024], comorbidity [AOR =2.29, 95% CI: 1.24, 4.24, P: 0.008], polypharmacy [AOR = 2.54, 95% CI: 1.35, 4.76, P: 0.004], and Antipsychotic Polypharmacy (APP) [AOR = 2.15, 95% CI: 1.21, 3.82, P: 0.009] were significantly associated with ACB.Conclusion: In this study, one-third of patients were exposed to high ACB. Old aged patients, those with comorbidity, polypharmacy, and APP need routine follow-up and screening in order to reduce high anticholinergic exposure.","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261481515"},"PeriodicalIF":5.0000,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498799/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253261481515","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Many drugs prescribed for individuals with schizophrenia have anticholinergic effects. When these medications are used together, they can create a substantial overall Anticholinergic Burden (ACB).

Objective: The aim of this study was to assess the prevalence of ACB and its predictors among patients with schizophrenia at selected comprehensive specialized hospitals in Northwest Ethiopia.

Design: A multicenter cross sectional study was conducted.

Methods: The study included 406 patients with schizophrenia at selected specialized hospitals in Northwest Ethiopia between June and August 2022. Study participants were recruited using systematic random sampling. The Anticholinergic Cognitive Burden Score (ACBS) was used to assess ACB. Data were entered using EpiData version 4.6.0 and analyzed with SPSS version 26. Multivariable logistic regression analysis was performed to determine the predictors of high ACB, with variables having a p-value < 0.05 at a 95% confidence interval considered statistically significant.

Results: The prevalence of high ACB was 34.2%. Older patients [Adjusted Odds Ratio (AOR) = 3.26, 95% CI: 1.17, 9.08 P: 0.024], comorbidity [AOR =2.29, 95% CI: 1.24, 4.24, P: 0.008], polypharmacy [AOR = 2.54, 95% CI: 1.35, 4.76, P: 0.004], and Antipsychotic Polypharmacy (APP) [AOR = 2.15, 95% CI: 1.21, 3.82, P: 0.009] were significantly associated with ACB.

Conclusion: In this study, one-third of patients were exposed to high ACB. Old aged patients, those with comorbidity, polypharmacy, and APP need routine follow-up and screening in order to reduce high anticholinergic exposure.

查看原文本刊更多论文

埃塞俄比亚西北部精神分裂症患者的抗胆碱能负荷及其预测因素：一项基于机构的横断面研究。

背景：许多给精神分裂症患者开的药物都有抗胆碱能作用。当这些药物一起使用时，它们会产生大量的整体抗胆碱能负担（ACB）。目的：本研究的目的是评估在埃塞俄比亚西北部选定的综合性专科医院精神分裂症患者中ACB的患病率及其预测因素。设计：采用多中心横断面研究。方法：对2022年6月至8月在埃塞俄比亚西北部选定的专科医院就诊的406例精神分裂症患者进行研究。研究参与者采用系统随机抽样方式招募。采用抗胆碱能认知负担评分（ACBS）评价ACB。数据录入采用EpiData 4.6.0版本，分析采用SPSS 26版本。采用多变量logistic回归分析确定高ACB的预测因素，在95%置信区间内p值< 0.05的变量认为具有统计学意义。结果：高ACB患病率为34.2%。老年患者[调整优势比(AOR) = 3.26, 95% CI: 1.17, 9.08 P: 0.024]、合并症[AOR =2.29, 95% CI: 1.24, 4.24, P: 0.008]、多种药物治疗[AOR = 2.54, 95% CI: 1.35, 4.76, P: 0.004]和抗精神病药物多种药物治疗（APP） [AOR = 2.15, 95% CI: 1.21, 3.82, P: 0.009]与ACB显著相关。结论：在本研究中，三分之一的患者暴露于高ACB。老年患者、合并症患者、多药患者和APP患者需要常规随访和筛查，以减少高抗胆碱能暴露。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Psychopharmacology Multiple-

CiteScore

7.90

自引率

2.40%

发文量

审稿时长

10 weeks

期刊介绍： Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.